Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
The spectrum of MOG autoantibody-associated demyelinating diseases.
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats.
[Epstein-Barr virus in the pathogenesis of multiple sclerosis (a review).]
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS.
Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
MiR-126: a novel route for natalizumab action?
Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Glial contributions to neural function and disease.
A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide.
Variables associated with patient activation in persons with multiple sclerosis.
Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis.
Keeping cool: use of air conditioning by australians with multiple sclerosis.
Individual variability in speed of information processing: An index of cognitive impairment in multiple sclerosis.
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.
Autoimmunity: Rubbing salt in the wound.
Progenitor-derived Oligodendrocyte Culture System from Human Fetal Brain.
Pages
« first
‹ previous
…
168
169
170
171
172
173
174
175
176
…
next ›
last »